Drugs in context · 2026
Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soriano Alex, Tascini Carlo, Falcone Marco, Morata Laura, Bongiovanni Marco, Pea Federico, Viale Pierluigi
Аннотация
BACKGROUND: Oritavancin is a long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) with potential applicability across difficult-to-treat Gram-positive infections such as osteomyelitis, bacteraemia and endocarditis. This systematic review evaluates the efficacy, safety and clinical use of oritavancin across on-label and off-label indications.
METHODS: MEDLINE and CENTRAL were searched (2011-2024) for randomized trials, retrospective cohorts, case series and real-world evidence reporting clinical outcomes following oritavancin administration. Risk of bias was assessed using Critical Appraisal Skills Programme (CASP) tools for randomized clinical trials and cohort studies.
RESULTS: Twenty-five studies met inclusion criteria: 11 evaluating ABSSSI (n=2311) and 14 assessing off-label use (n=692), including for osteomyelitis, bacteraemia and endocarditis. Across ABSSSI randomized clinical trials, oritavancin demonstrated clinical cure rates of 79.6-83.3%, comparable to those of vancomycin. In retrospective studies, clinical success rates ranged from 85% to 88% in ABSSSI retrospective studies and from 70% to 100% in off-label studies. Adverse events were primarily mild to moderate.
CONCLUSIONS: Oritavancin is effective for ABSSSI and may be a promising treatment alternative for selected Gram-positive off-label indications requiring prolonged therapy. Standardized dosing strategies and prospective trials are needed to define optimal regimens for off-label indications.
METHODS: MEDLINE and CENTRAL were searched (2011-2024) for randomized trials, retrospective cohorts, case series and real-world evidence reporting clinical outcomes following oritavancin administration. Risk of bias was assessed using Critical Appraisal Skills Programme (CASP) tools for randomized clinical trials and cohort studies.
RESULTS: Twenty-five studies met inclusion criteria: 11 evaluating ABSSSI (n=2311) and 14 assessing off-label use (n=692), including for osteomyelitis, bacteraemia and endocarditis. Across ABSSSI randomized clinical trials, oritavancin demonstrated clinical cure rates of 79.6-83.3%, comparable to those of vancomycin. In retrospective studies, clinical success rates ranged from 85% to 88% in ABSSSI retrospective studies and from 70% to 100% in off-label studies. Adverse events were primarily mild to moderate.
CONCLUSIONS: Oritavancin is effective for ABSSSI and may be a promising treatment alternative for selected Gram-positive off-label indications requiring prolonged therapy. Standardized dosing strategies and prospective trials are needed to define optimal regimens for off-label indications.